This early-stage venture fund, with offices in Western Europe, is led by a team with deep expertise across venture funding, company building, and therapeutic development. The firm is currently focused on cell and gene therapy, with particular interest in the manufacturing technologies that support these modalities.
The firm is especially interested in therapeutic platforms at the pre-clinical stage, including cutting-edge cell therapies for regenerative medicine and autoimmune conditions that require localized manufacturing capabilities. It seeks to support breakthrough technologies at the seed stage.
The firm typically takes an active role in its portfolio companies, frequently leading rounds, providing strategic guidance, and ensuring board-level engagement, either by taking a board seat directly or placing a qualified expert. In addition to company creation, the firm also invests in existing ventures, often syndicating with other institutional investors to support early-stage growth.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment